Cargando…

Breakthrough COVID-19 and casirivimab-imdevimab treatment during a SARS-CoV-2 B1.617.2 (Delta) surge

INTRODUCTION: : The impact of vaccination and casirivimab-imdevimab monoclonal antibody treatment on the clinical outcome of COVID-19 during a period of SARS-CoV-2 Delta surge is not known. AIM AND METHODS: : All patients with COVID-19 at our facilities in the US Midwest were enrolled to assess brea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bierle, Dennis M., Ganesh, Ravindra, Razonable, Raymund R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Authors. Published by Elsevier B.V. 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8574126/ https://www.ncbi.nlm.nih.gov/pubmed/34775142 http://dx.doi.org/10.1016/j.jcv.2021.105026

Ejemplares similares

Curbing the Delta Surge: Clinical Outcomes After Treatment With Bamlanivimab-Etesevimab, Casirivimab-Imdevimab, or Sotrovimab for Mild to Moderate Coronavirus Disease 2019
por: Razonable, Raymund R., et al.
Publicado: (2022)

Effectiveness of Casirivimab-Imdevimab Monoclonal Antibody Treatment Among High-Risk Patients With Severe Acute Respiratory Syndrome Coronavirus 2 B.1.617.2 (Delta Variant) Infection
por: Al-Obaidi, Mohanad M, et al.
Publicado: (2022)

Casirivimab–Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19
por: Razonable, Raymund R., et al.
Publicado: (2021)

Casirivimab/Imdevimab: First Approval
por: Deeks, Emma D.
Publicado: (2021)

Casirivimab and imdevimab for COVID-19
Publicado: (2022)

Increasing severity of COVID-19 in pregnancy with Delta (B.1.617.2) variant surge
por: Adhikari, Emily H., et al.
Publicado: (2022)

Severe breakthrough COVID-19 cases in the SARS-CoV-2 delta (B.1.617.2) variant era
por: Wang, Stephen Y, et al.
Publicado: (2022)

Casirivimab/imdevimab: Various toxicities: 2 case reports
Publicado: (2022)

Rates of Severe Outcomes After Bamlanivimab-Etesevimab and Casirivimab-Imdevimab Treatment of High-Risk Patients With Mild to Moderate Coronavirus Disease 2019
por: O’Horo, John, et al.
Publicado: (2022)

Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV-2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use case
por: Tatham, Lee, et al.
Publicado: (2023)

Effects of Casirivimab/Imdevimab Monoclonal Antibody Treatment among Vaccinated Patients Infected by SARS-CoV-2 Delta Variant
por: Cicchitto, Gaetano, et al.
Publicado: (2022)

Casirivimab/imdevimab: Lack of efficacy: case report
Publicado: (2022)

Use of Casirivimab and Imdevimab for the Treatment of COVID-19
por: Liu, Ryan, et al.
Publicado: (2022)

Monoclonal Antibody Therapy in a Vaccine Breakthrough SARS-CoV-2 Hospitalized Delta (B.1.617.2) Variant Case
por: Connor, Bradley A, et al.
Publicado: (2021)

SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion
por: Mlcochova, Petra, et al.
Publicado: (2021)

Clinical efficacy of casirivimab-imdevimab antibody combination treatment in patients with COVID-19 Delta variant
por: Miyashita, Naoyuki, et al.
Publicado: (2022)

Casirivimab - Imdevimab in Covid 19 – Early Indian experience
por: Venkitakrishnan, Rajesh, et al.
Publicado: (2022)

Casirivimab and Imdevimab for the Treatment of Hospitalized Patients With COVID-19
por: Somersan-Karakaya, Selin, et al.
Publicado: (2022)

Codon usage divergence in Delta variants (B.1.617.2) of SARS-CoV-2
por: Li, Gun, et al.
Publicado: (2022)

Age-Varying Susceptibility to the Delta Variant (B.1.617.2) of SARS-CoV-2
por: Chun, June Young, et al.
Publicado: (2022)

Charge transport properties of SARS-CoV-2 Delta variant (B.1.617.2)
por: He, Lijun, et al.
Publicado: (2022)

Enhanced fitness of SARS-CoV-2 B.1.617.2 Delta variant in ferrets
por: Sun, Xiangjie, et al.
Publicado: (2023)

Casirivimab-imdevimab neutralizing SARS-CoV-2: post-infusion clinical events and their risk factors
por: Yoshida, Junichi, et al.
Publicado: (2022)

Casirivimab-Imdevimab (REGN-COV2) for Mild to Moderate SARS-CoV-2 Infection in Kidney Transplant Recipients
por: Liu, Esther C., et al.
Publicado: (2021)

Multisystem Inflammatory Syndrome in an Adult Who Received Casirivimab-Imdevimab (REGEN-COV)
por: Singh, Gurdeep, et al.
Publicado: (2022)

A SEVERE ADVERSE DRUG REACTION (ADR) TO REGEN-COV (CASIRIVIMAB AND IMDEVIMAB)
por: Abou-Jaoude, E., et al.
Publicado: (2022)

Transmission of B.1.617.2 Delta variant between vaccinated healthcare workers
por: Kemp, Steven A., et al.
Publicado: (2022)

Analysis of the Delta Variant B.1.617.2 COVID-19
por: Shiehzadegan, Shayan, et al.
Publicado: (2021)

Impact of SARS-CoV-2 delta variant (B.1.617.2) in surging second wave of COVID-19 and efficacy of vaccines in tackling the ongoing pandemic
por: Tareq, Abu Montakim, et al.
Publicado: (2021)

Severe Breakthrough COVID-19 Cases during Six Months of Delta Variant (B.1.617.2) Domination in Poland
por: Rzymski, Piotr, et al.
Publicado: (2022)

Doubtful clinical benefit of casirivimab-imdevimab treatment for disease severity outcome of high-risk patients with SARS-CoV-2 delta variant infection
por: Shopen, Noah, et al.
Publicado: (2022)

Treatment of COVID-19 with monoclonal antibodies casirivimab and imdevimab in pregnancy
por: Folkman, Rebecca, et al.
Publicado: (2022)

Effectiveness of Subcutaneous Casirivimab and Imdevimab in Ambulatory Patients with COVID-19
por: Jalbert, Jessica J., et al.
Publicado: (2022)

Rapid detection of the widely circulating B.1.617.2 (Delta) SARS-CoV-2 variant
por: Rosato, Adriana E., et al.
Publicado: (2022)

Epidemiological analysis of SARS-COV-2 B.1.617.2 (delta variant) transmission in an educational institute
por: Vishnu Prasad, S., et al.
Publicado: (2022)

B.1.617.2 (Delta) Variant of SARS-CoV-2: features, transmission and potential strategies
por: Zhan, Yan, et al.
Publicado: (2022)

SARS-CoV-2 RT-PCR to Screen for B.1.617.2 (Delta) Variant of Concern
por: Lowry, Kym, et al.
Publicado: (2022)

Safety of casirivimab/imdevimab administration in a SARS-CoV-2 positive maintenance dialysis patient in Japan
por: Terakawa, Kanako, et al.
Publicado: (2022)

Effect of Casirivimab/Imdevimab Treatment on Serum Type I Interferon Levels in SARS-CoV-2 Infection
por: Nagaoka, Kentaro, et al.
Publicado: (2022)

Clinical Prioritization of Antispike Monoclonal Antibody Treatment of Mild to Moderate COVID-19
por: Razonable, Raymund R., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_traoq64a31s3t0pcbh98b2n0gr